SYNDAX PHARMACEUTICALS ($SNDX) posted quarterly earnings results on Monday, May 5th. The company reported earnings of -$0.98 per share, beating estimates of -$1.36 by $0.38. The company also reported revenue of $20,040,000, beating estimates of $14,721,547 by $5,318,453.
You can see Quiver Quantitative's $SNDX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SYNDAX PHARMACEUTICALS Insider Trading Activity
SYNDAX PHARMACEUTICALS insiders have traded $SNDX stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $SNDX stock by insiders over the last 6 months:
- MICHAEL A METZGER (Chief Executive Officer) has made 0 purchases and 2 sales selling 21,102 shares for an estimated $323,581.
- NEIL GALLAGHER (President, Head of R&D) sold 4,618 shares for an estimated $71,597
- KEITH A. GOLDAN (Chief Financial Officer) sold 3,777 shares for an estimated $58,558
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SYNDAX PHARMACEUTICALS Hedge Fund Activity
We have seen 119 institutional investors add shares of SYNDAX PHARMACEUTICALS stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 4,425,677 shares (+498.9%) to their portfolio in Q4 2024, for an estimated $58,507,449
- GOLDMAN SACHS GROUP INC added 4,338,485 shares (+269.1%) to their portfolio in Q4 2024, for an estimated $57,354,771
- EVERSEPT PARTNERS, LP removed 3,761,913 shares (-91.6%) from their portfolio in Q4 2024, for an estimated $49,732,489
- KYNAM CAPITAL MANAGEMENT, LP added 2,677,075 shares (+45.8%) to their portfolio in Q4 2024, for an estimated $35,390,931
- ORBIMED ADVISORS LLC removed 1,925,300 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $25,452,466
- AVORO CAPITAL ADVISORS LLC removed 1,613,437 shares (-41.5%) from their portfolio in Q4 2024, for an estimated $21,329,637
- SOLEUS CAPITAL MANAGEMENT, L.P. added 1,401,016 shares (+128.4%) to their portfolio in Q4 2024, for an estimated $18,521,431
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
